about
Clinical significance of phosphatidyl inositol synthase overexpression in oral cancer.Nuclear S100A7 is associated with poor prognosis in head and neck cancer.Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer.Promoter hypermethylation in Indian primary oral squamous cell carcinoma.Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.Retinoids as chemopreventive agents.Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancerNuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer.Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosisLinks between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases.Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco.Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma.Establishment and characterisation of two novel breast cancer cell lines.Establishment and characterization of a cell line from smokeless tobacco associated oral squamous cell carcinoma.S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.Differential expression of retinoic acid receptors in normal and malignant esophageal tissues.Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.Smokeless tobacco (khaini) extracts modulate gene expression in epithelial cell culture from an oral hyperplasia.Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapyCo-expression of colligin and collagen in oral submucous fibrosis: plausible role in pathogenesisPrognostic factors in betel and tobacco related oral cancerThermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanomaP-glycoprotein is positively correlated with p53 in human oral pre-malignant and malignant lesions and is associated with poor prognosisCurcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cellsMGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosisAlterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinomaCytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patientsHeterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinomaPrognostic significance of nuclear pSTAT3 in oral cancer
P50
Q33567362-EB0F8053-8CF7-4722-AC72-6EA376F1854AQ33651153-98933237-D888-432A-96F6-4903EFB0B1A0Q33900846-1D4A1C6D-B68D-49D9-958F-5F79ABA17A62Q34159082-A57D4372-61F1-4416-9FC5-2ED3C6876C9EQ34807135-7833B6E5-183D-424C-A716-E9CCEE05CD02Q35072838-7BCB829C-955E-44ED-9AC3-2795323871A0Q35131461-F1603222-6058-491F-BD00-BB0F45E054C6Q35818215-D894BC30-3983-4932-B3A0-96D7966A12F0Q36006304-E9D9A60D-C476-473B-8265-8BCCD7FDE169Q36078946-DF774C57-58F7-435D-9C41-D974C587EBF7Q36541112-B8E8E444-0CB5-4ED1-A522-C207146CAE97Q38303784-4A07AD97-A5A4-4188-A03A-C173EA33A3EFQ39210485-72058456-6D86-42BE-823A-827D42441938Q39696941-B05ABD3D-4615-4476-903C-FF0E57F602FBQ40062858-B0B38BB6-769D-4BF7-B383-E0878DA6B4A7Q40633874-A9833526-62CC-4961-B542-BE92AF66CB53Q43972741-4DF75E7A-0223-4C6B-AEF4-3A3B22D93F06Q44979535-B1FDF1BF-7D9C-4579-A7E4-7AEC38516E48Q46552631-F4EDE25B-B74F-4879-9C00-598AADAB2D68Q53356816-D12B9883-710A-472B-A153-D501C9A3374DQ71822946-42462AB8-D1EA-4907-A47D-53F98E5041B8Q73711667-3BE739E2-73F5-460A-A2A9-C12BB999E1B6Q74444049-89BA8475-6C9A-41D4-B412-01BB33C31B9CQ74777789-A8EABE2B-6EA7-44E9-872C-C33A7A7753BCQ78167065-03AA86BB-852F-45B9-9485-C7BADFA54DD2Q80333106-23063B23-E85E-40C7-92D0-2FFFD27B4737Q80333284-C09812CD-9B00-4401-83B1-4821BD5D15BDQ80379601-A5EAD0E7-2338-49CF-8D01-D7E07137AF8CQ83184081-5ED67257-E5DB-4869-A0A6-33D551F6531DQ84110958-29E3B1A7-756D-4482-A78D-2A5D68F5EE5DQ84588056-D14E8B03-3A20-4FAA-8282-33E38389B061
P50
description
Indian biomedical researcher
@en
wetenschapper
@nl
name
Jatinder Kaur
@en
Kaur J
@nl
type
label
Jatinder Kaur
@en
Kaur J
@nl
altLabel
Kaur J
@en
prefLabel
Jatinder Kaur
@en
Kaur J
@nl
P106
P31
P496
0000-0003-1650-0707